Pegfilgrastim Biosimilars: Blue Ocean or Red Ocean?

How Pillar 2 Data Decodes a Hyper-Consolidated Market

The Saturated Cliff: A 90% Revenue Collapse

Amgen’s Neulasta (pegfilgrastim) is the ultimate cautionary tale of what happens when a blockbuster drug hits the generic pipeline wall. In 2016, Neulasta was a formatting powerhouse, racking up $4.7 billion in worldwide sales. By the end of full-year 2025, that figure plummeted to a mere $435 million - a devastating decline of more than 90% in under a decade.

The Illusion of Competition: Consolidation Takes Over

The market has shifted from competitive to hyper-consolidated. Following Coherus BioSciences' 2025 exit, Accord BioPharma/Intas now controls two of the eight approved US brands, employing a dual-brand strategy with Udenyca and Ennumo. This consolidation underscores that the market is no longer driven by new entries, but by strategic acquisitions.

The Billion-Dollar Question for Portfolio Strategists

With fierce competition and market consolidation, the core challenge is whether to develop new biosimilars or acquire existing positions.

So here is the real question: Is pegfilgrastim still a market you would enter fresh - or is the opportunity now in acquiring an existing position rather than building one from scratch?

Success now hinges on supply chain security and device innovation, rather than solely on development costs.

Unblinding the Market with Pipeline Intelligence (Pillar 2 Data)

While public data shows 10 approved biosimilars in the EU, our Pipeline Intelligence identifies 15+ active CTD dossiers currently in circulation, representing the true, hidden competitive landscape. Using Pillar 2 Data, you can identify:

• Hidden competitors with ready-to-file dossiers.
• Actual regulatory readiness of market players.
• Opportunities for strategic licensing rather than costly R&D.

Stress-Test Before You Invest

Avoid a multi-million dollar gamble by utilizing Pipelinepharma’s data to map consolidation trends.

How is your team reading this pipeline?

Is the pegfilgrastim window completely closed for new entries, or is there still a niche for device innovation? Search our CTD Dossier Marketplace to analyze the real-time competitor density, or connect with our business development experts to eliminate your portfolio's strategic blind spots.

Sources: EMA recommends approval for biosimilar pegfilgrastim Cavoley — GaBI Online, Aug 20, 2026; FDA approves Ennumo as eighth pegfilgrastim biosimilar - GaBI Online, Jul 3, 2026; Amgen Q4/FY2025 Financial Results, Feb 2026; Coherus Oncology Q2 2026 Financial Results, Aug 5, 2026